Skip to main content
OpenTrials
Completed

NCT Number: NCT04448483

Clinical Study for Upper Limb Motor Restoration in Chronic Stroke Patients Using Personalized Neuro-technologies

This study aims to evaluate safety, tolerability and efficacy of a new treatment for upper limb motor rehabilitation after severe stroke using non-invasive neurotechnologies. The investigational system is used alone or coupled with brain stimulation provided by transcranic direct current stimulation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinique Romande de Readaptation (CRR)

Sion, Switzerland

About this study

This study aims at providing two interventions:

In the first intervention, a brain computer interface able to non-invasively detect motor intention from the non-invasive measure of brain activity by using electroencephalography (BrainVision, V-amp) activates a robotic glove (Gloreha Sinfonia, Idrogenet Srl) that will assist-as-needed hand movements and paretic upper limb functional electric stimulation (RehaStim, Hasomed). The latter will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb. The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release.

In the second intervention, non-invasive brain stimulation (DC-Stimulator, NeuroConn) in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.

Each participant will perform a minimum of 11 rehabilitative sessions for the first intervention and a minimum of 11 rehabilitative sessions for the second intervention, for a total minimum of 22 rehabilitative sessions. If the participant recovers with the intervention, the relative rehabilitative session continues to be proposed until patients will reaches a "plateau". The intervention will switch from 1 to 2 if the participant does not improve anymore with the 1st intervention. If the patient does not improve anymore with the 2nd intervention the interventional part of the trial will be finished. The intervention(s) will terminate also if the participant continues to progress after 6 months of inclusion. As the study is especially designed for personalization of intervention for every patient, it is not possible to determine a priori the number of sessions for each participant, because they depend on the response of each participant to the intervention. The duration of each rehabilitative visit is about two and half hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic cerebral stroke patients (at least 6 months after the event).
  • First ever clinical manifest stroke.
  • No or minimal residual voluntary finger extension.
  • Upper limb FM score < 20.
  • Age > 18 years.
  • Right or left severe hemiparesis.
  • Ischemic or hemorrhagic stroke with intact hand knob area.

Exclusion criteria

  • Patient with an active implantable device or wearing an active device.
  • Occurrence of new clinically manifest stroke.
  • Cerebellar stroke.
  • Drug or alcohol dependency.
  • Pregnancy.
  • Refusal to perform any proposed pregnancy test for women in childbearing age (18 to menopausal age).
  • Psychotic symptoms and significant psychopharmacologic treatments with neuroleptics and/or Lithium and antiepileptics
  • Use of medication that significantly interacts with non-invasive brain stimulation being benzodiazepines, tricyclic antidepressant and antipsychotics.
  • Severe spasticity that prevent the patient to use the robotic orthosis (indicative Modified Ashworth Scale > 3).
  • Severe cognitive problems and severe neglect.
  • Physical features impeding the recording of brain signals or the muscular signals stimulation (voluminous hair and large amount of subcutaneous fat in the arms).
  • Severe heart disease.
  • Allergy to latex and dermatitis.
  • Epileptic seizures or using medications that reduce the threshold for epileptic seizures.
  • Travel distance to the study site more than 70 Km.
  • Involvement in other clinical treatment trials related to stroke.
  • Participant does not want to be informed about the potential fortuitous discoveries that may contribute to the prevention, diagnosis and treatment of existing or probable diseases in the future.

Treatment and study plan

Paretic upper limb functional electric stimulation through RehaStim

Device

The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.

The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release.

Non-invasive transcranial current stimulation through DC-Stimulator

Device

Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.

Primary outcomes

  1. Change in functional improvement of upper limbs along training sessions

    Time frame: 10 months average

    Measurement of improvement before and after training of upper limb, using Fugl-Meyer (FMA) scale (0-66).

    FMA is a stroke specific index to estimate motor function. Measurements are performed every second training session and at the evaluation visit.

  2. Change in speed and coordination of the affected side

    Time frame: 10 months average

    Measurement of speed and coordination of the affected side are performed using FMA modified score, max 54.

    Measurements are performed every second training session.

  3. Change in sensorimotor status in the two upper limbs

    Time frame: 10 months average

    Measurement of sensorimotor status in the two upper limbs, using Fugl-Meyer (FMA) scale (0-66).

    Measurements are performed at the evaluation visit.

  4. Action Reach Arm Test (ARAT)

    Time frame: 10 months average

    Upper limb functions changes measured by the ARAT test (ARAT scale: 0-57) in the two upper limbs.

    Measurements are performed at the evaluation visit.

  5. Fatigue Visual Analog Scale (VAS)

    Time frame: 10 months average

    Measurement of fatigue is made with the Visual Analog Scale (VAS; 0-100). Measurements are performed every second training session.

  6. Rivermead Assessment of Somatosensory Performance (RASP)

    Time frame: 10 months average

    Somatosensory function are measured with RASP (RASP; 0-210) in the two upper limbs.

    Measurements are performed at the evaluation visit.

Secondary outcomes

  1. Brain stimulation effectiveness in BCI-aided motor therapy

    Time frame: 10 months average

    The measurement of the effectiveness of brain stimulation is measured by FMA scores of all patients at initial, inter-intervention and final evaluation. This measurement is made between the end and the beginning of each intervention for each patient.

    Comparison is made by using one-way ANOVA if data normally distributed, or Kruskal Wallis test if otherwise. Secondary analysis measures are calculated for each patient once they complete the study. It will consist in the evaluation of effectiveness of BCI-aided motor therapy without and with brain stimulation. Group comparison is done with inferential statistics for full and partial populations. Similar comparisons and judgement criteria are applied for clinical scales and questionnaires.

Sponsors and collaborators

Lead sponsor

Wyss Center for Bio and Neuroengineering

Other

Collaborators

  • Ecole Polytechnique Fédérale de Lausanne

Registry information

Official study title

Accident Vasculaire cérébral et Apport Des Neurotechnologies individualisées Chez la Personne Avec Une hémiparésie Chronique : Une Etude Clinique Prospective Visant à Restaurer la mobilité du Membre supérieur

Acronym: AVANCER

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jun 26, 2020
Registry last updated
Dec 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.